As we continue in our series of analyzing warning letter findings, we move from clinical investigators to IRBs, assessing their level of compliance with 21 CFR Part 56.
A random review of warning letters issued to IRBs in recent years showed 3 key areas in need of improvement including written procedures, timeliness of continuing review, and adequate documentation.
Complete the form to download the guide.
